IL17A and acute respiratory distress syndrome: This validates their therapeutic potential in ALI even from the early stages characterized by elevated levels of interleukin-17A (IL-17A) in the blood and BALF [8,9] and an imbalance between Th17 and Treg cells, favoring a Th17 shift [10].